These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
252 related articles for article (PubMed ID: 16426877)
21. [No potentiation of fentanyl by use of transdermal buprenorphine in patients undergoing fast-track anesthesia for open-heart surgery]. Freye E; Hartung E; Levy JV Anasthesiol Intensivmed Notfallmed Schmerzther; 2006 Feb; 41(2):86-92. PubMed ID: 16493560 [TBL] [Abstract][Full Text] [Related]
22. Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine. Kress HG Eur J Pain; 2009 Mar; 13(3):219-30. PubMed ID: 18567516 [TBL] [Abstract][Full Text] [Related]
23. Transdermal buprenorphine in the treatment of chronic pain. Sittl R Expert Rev Neurother; 2005 May; 5(3):315-23. PubMed ID: 15938664 [TBL] [Abstract][Full Text] [Related]
24. [Application of a seven-day buprenorphine transdermal patch in multimorbid patients on long-term ibuprofen or diclofenac]. Böhme K; Heckes B; Thomitzek K MMW Fortschr Med; 2011 Jan; 152 Suppl 4():125-32. PubMed ID: 21598463 [TBL] [Abstract][Full Text] [Related]
25. Short- and intermediate-term efficacy of buprenorphine TDS in chronic painful neuropathies. Penza P; Campanella A; Martini A; Melli G; Lombardi R; Camozzi F; Devigili G; Lauria G J Peripher Nerv Syst; 2008 Dec; 13(4):283-8. PubMed ID: 19192068 [TBL] [Abstract][Full Text] [Related]
26. High dose transdermal buprenorphine for moderate to severe pain in spanish pain centres--a retrospective multicenter safety and efficacy study. Barutell C; Camba A; González-Escalada JR; Rodríguez M; Pain Pract; 2008; 8(5):355-61. PubMed ID: 18662364 [TBL] [Abstract][Full Text] [Related]
27. Use of transdermal clonidine in chronic hemodialysis patients. Rosansky SJ; Johnson KL; McConnell J Clin Nephrol; 1993 Jan; 39(1):32-6. PubMed ID: 8428405 [TBL] [Abstract][Full Text] [Related]
28. Transdermal buprenorphine (Butrans) for chronic pain. Med Lett Drugs Ther; 2011 Apr; 53(1362):31-2. PubMed ID: 21502936 [TBL] [Abstract][Full Text] [Related]
29. Gastrointestinal symptoms under opioid therapy: a prospective comparison of oral sustained-release hydromorphone, transdermal fentanyl, and transdermal buprenorphine. Wirz S; Wittmann M; Schenk M; Schroeck A; Schaefer N; Mueller M; Standop J; Kloecker N; Nadstawek J Eur J Pain; 2009 Aug; 13(7):737-43. PubMed ID: 18977159 [TBL] [Abstract][Full Text] [Related]
30. Effects of intravenous patient-controlled analgesia with buprenorphine and morphine alone and in combination during the first 12 postoperative hours: a randomized, double-blind, four-arm trial in adults undergoing abdominal surgery. Oifa S; Sydoruk T; White I; Ekstein MP; Marouani N; Chazan S; Skornick Y; Weinbroum AA Clin Ther; 2009 Mar; 31(3):527-41. PubMed ID: 19393843 [TBL] [Abstract][Full Text] [Related]
31. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis. Brandi L Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159 [TBL] [Abstract][Full Text] [Related]
32. The effect of transdermal fentanyl treatment on serum cortisol concentrations in patients with non-cancer pain. Ozyuvaci E; Yanmaz Alnigenis N; Altan A J Pain Symptom Manage; 2004 Sep; 28(3):277-81. PubMed ID: 15336341 [TBL] [Abstract][Full Text] [Related]
33. Transdermal fentanyl in cachectic cancer patients. Heiskanen T; Mätzke S; Haakana S; Gergov M; Vuori E; Kalso E Pain; 2009 Jul; 144(1-2):218-22. PubMed ID: 19442446 [TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of transdermal buprenorphine: a randomized, placebo-controlled trial in 289 patients with severe cancer pain. Poulain P; Denier W; Douma J; Hoerauf K; Samija M; Sopata M; Wolfram G J Pain Symptom Manage; 2008 Aug; 36(2):117-25. PubMed ID: 18411010 [TBL] [Abstract][Full Text] [Related]
35. [Treatment of chronic osteoarthritis pain: effectivity and safety of a 7 day matrix patch with a low dose buprenorphine]. Schutter U; Ritzdorf I; Heckes B MMW Fortschr Med; 2008 Jun; 150 Suppl 2():96-103. PubMed ID: 18712130 [TBL] [Abstract][Full Text] [Related]
36. Switching from transdermal drugs: an observational "N of 1" study of fentanyl and buprenorphine. Mercadante S; Porzio G; Fulfaro F; Aielli F; Verna L; Ficorella C; Casuccio A; Riina S; Intravaia G; Mangione S J Pain Symptom Manage; 2007 Nov; 34(5):532-8. PubMed ID: 17629666 [TBL] [Abstract][Full Text] [Related]
37. Buprenorphine transdermal system in adults with chronic low back pain: a randomized, double-blind, placebo-controlled crossover study, followed by an open-label extension phase. Gordon A; Callaghan D; Spink D; Cloutier C; Dzongowski P; O'Mahony W; Sinclair D; Rashiq S; Buckley N; Cohen G; Kim J; Boulanger A; Piraino PS; Eisenhoffer J; Harsanyi Z; Darke AC; Michalko KJ Clin Ther; 2010 May; 32(5):844-60. PubMed ID: 20685494 [TBL] [Abstract][Full Text] [Related]
38. [Effects of transdermal buprenorphine in cancer patients. Results from the Cancer Pain Outcome Research (CPOR) Study Group]. Greco MT; Deandrea S; Corli O; Montanari M; Caraceni A; Apolone G; Recenti Prog Med; 2008 Nov; 99(11):538-51. PubMed ID: 19209537 [TBL] [Abstract][Full Text] [Related]
39. Serum concentrations of buprenorphine after oral and parenteral administration in male mice. Kalliokoski O; Jacobsen KR; Hau J; Abelson KS Vet J; 2011 Feb; 187(2):251-4. PubMed ID: 20045358 [TBL] [Abstract][Full Text] [Related]